Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $150.00 short put and a strike $140.00 long put offers a potential 19.76% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $150.00 by expiration. The full premium credit of $1.65 would be kept by the premium seller. The risk of $8.35 would be incurred if the stock dropped below the $140.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 66.12 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Bull market always has skeptics: Cramer
Wed, 20 Nov 2013 23:00:00 GMT
CNBC – Despite the wave of negativity that swept today's markets following the release of Fed minutes, Mad Money host Jim Cramer still thinks we are in a bull market.
Celgene Corporation (CELG) Highlighted As Momo Momentum Stock
Wed, 20 Nov 2013 15:37:00 GMT
TheStreet – Trade-Ideas LLC identified Celgene Corporation (CELG) as a momo momentum candidate
Alliqua Inc. Amplifies Value Proposition With Celgene's Licensing Deal
Wed, 20 Nov 2013 13:45:27 GMT
Seeking Alpha – The wound therapy industry may not be the most thrilling biotech niche on the surface, but the multi-billion dollar market's need for innovation has created an opportunity for small prospecting companies …
Celgene Vs. Rivals In Psoriatic Arthritis Drug Race
Wed, 20 Nov 2013 09:16:40 GMT
Seeking Alpha – Apremilast, an experimental small-molecule drug from Celgene ( CELG ), has proven effective against psoriatic arthritis after 52 weeks. The results from the Phase 3 trials were reported in October at the …
First Week of CELG July 2014 Options Trading
Tue, 19 Nov 2013 16:35:00 GMT
Forbes – Investors in Celgene Corp. (NASD: CELG) saw new options become available this week, for the July 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent […]
Also on Market Tamer…
Follow Us on Facebook